This Canadian biotech stock is very undervalued, analyst says

Research Capital analyst André Uddin re-initiated coverage of Spectral Medical (Spectral Medical Stock Quote, Chart, News, Analysts, Financials TSX:EDT) on Oct. 16 with a “Speculative Buy” rating and a C$3.50 price target, citing recent pivotal trial success, a large untapped U.S. market in septic shock, and a strong commercialization partner as key catalysts for a re-rating ahead of the company’s planned FDA filing.

“Spectral is targeting one of the largest unmet needs in critical care medicine,” Uddin said. “With positive Phase 3 TIGRIS data, exclusive North American rights to PMX, and a U.S. partner that covers roughly half of the ICU device market, the company is well positioned for a transformational period over the next 18 months.”

Toronto-based Spectral Medical is a Canadian theranostics company focused on precision-medicine solutions for septic shock, integrating its proprietary Endotoxin Activity Assay diagnostic with Toraymyxin, a polymyxin B hemoperfusion cartridge that removes endotoxin from the bloodstream. Spectral holds exclusive commercialization rights for PMX in the U.S. and Canada, and if approved, it would be the only available therapy for sepsis in the United States.

Uddin noted that the company’s TIGRIS trial (n = 157) confirmed the mortality-reduction trend first observed in a subgroup analysis of the earlier EUPHRATES trial, which identified patients with EAA levels between 0.60 and 0.89 as the key responder population. Combined TIGRIS and EUPHRATES data met both the 28-day and 90-day mortality endpoints using Bayesian analysis, showing statistically significant benefit. A Premarket Approval (PMA) submission to the FDA is expected by January 2026, with a potential U.S. launch in late 2026.

Spectral’s distribution partner, Vantive (formerly Baxter’s renal-care business, now owned by The Carlyle Group), provides deep access to intensive-care units, with an estimated 50% share of the U.S. critical-care device market.

“This partnership gives Spectral immediate commercial reach and credibility as PMX approaches approval,” Uddin said.

He highlighted the scale of the opportunity, pointing out that sepsis affects 1.7 million Americans annually, with roughly 140,000 cases of endotoxic septic shock, the specific segment targeted by PMX. Mortality rates remain near 30%, and treatment costs per patient range from US$32,000 to US$69,000, underscoring the potential health-system impact.

Spectral’s management team also brings strong sector expertise, led by CEO Chris Seto, a former investment banker with more than 25 years of capital markets experience, and Dr. John Kellum, former Director of Critical Care Nephrology at the University of Pittsburgh.

“We believe Spectral’s recent clinical success, regulatory momentum, and strategic distribution partnership position it for meaningful value creation,” Uddin said.

His C$3.50 target is based on a discounted cash-flow analysis of projected PMX revenues from 2025 to 2038 in the U.S. and Canada.

“Assuming timely approval and launch, we expect Spectral to be re-rated as investors recognize the scale of its addressable market and the uniqueness of its PMX-EAA platform,” Uddin said.

-30-